{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T13:04:46Z","timestamp":1790687086928,"version":"4.1.0"},"reference-count":37,"publisher":"Oxford University Press (OUP)","issue":"3","funder":[{"DOI":"10.13039\/501100001711","name":"Swiss National Science Foundation","doi-asserted-by":"crossref","award":["3347CO-108792"],"award-info":[{"award-number":["3347CO-108792"]}],"id":[{"id":"10.13039\/501100001711","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,2,28]]},"DOI":"10.1093\/ecco-jcc\/jjx158","type":"journal-article","created":{"date-parts":[[2017,11,19]],"date-time":"2017-11-19T07:07:08Z","timestamp":1511075228000},"page":"347-354","source":"Crossref","is-referenced-by-count":60,"title":["Expression Patterns of TNF\u03b1, MAdCAM1, and STAT3 in Intestinal and Skin Manifestations of Inflammatory Bowel Disease"],"prefix":"10.1093","volume":"12","author":[{"given":"Stephan R","family":"Vavricka","sequence":"first","affiliation":[{"name":"Division of Gastroenterology and Hepatology, University Hospital Zurich, Switzerland"},{"name":"Division of Gastroenterology and Hepatology, Triemli Hospital Zurich, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose A","family":"Galv\u00e1n","sequence":"additional","affiliation":[{"name":"Institute of Pathology, University of Bern, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather","family":"Dawson","sequence":"additional","affiliation":[{"name":"Institute of Pathology, University of Bern, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex","family":"Soltermann","sequence":"additional","affiliation":[{"name":"Department of Pathology, University Hospital Zurich, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luc","family":"Biedermann","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, University Hospital Zurich, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Scharl","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, University Hospital Zurich, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alain M","family":"Schoepfer","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, University Hospital Lausanne-CHUV, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerhard","family":"Rogler","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, University Hospital Zurich, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mareike B","family":"Prinz Vavricka","sequence":"additional","affiliation":[{"name":"Private Practice for Dermatology, Praxis Dr. R\u00fcmmelein AG, Zurich, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luigi","family":"Terracciano","sequence":"additional","affiliation":[{"name":"Department of Pathology, University Hospital Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Navarini","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University Hospital Zurich, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inti","family":"Zlobec","sequence":"additional","affiliation":[{"name":"Institute of Pathology, University of Bern, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Lugli","sequence":"additional","affiliation":[{"name":"Institute of Pathology, University of Bern, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Greuter","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, University Hospital Zurich, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2017,12,21]]},"reference":[{"key":"key\n\t\t\t\t2018121209541492500_CIT0001","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1146\/annurev-immunol-030409-101225","article-title":"Inflammatory bowel disease","volume":"28","author":"Kaser","year":"2010","journal-title":"Annu Rev Immunol"},{"key":"key\n\t\t\t\t2018121209541492500_CIT0002","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1056\/NEJMoa1215734","article-title":"Vedolizumab as induction and maintenance therapy for ulcerative colitis","volume":"369","author":"Feagan","year":"2013","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2018121209541492500_CIT0003","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1215739","article-title":"Vedolizumab as induction and maintenance therapy for Crohn\u2019s disease","volume":"369","author":"Sandborn","year":"2013","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2018121209541492500_CIT0004","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/1476-9255-7-41","article-title":"Anti-inflammatory activity and neutrophil reductions mediated by the JAK1\/JAK3 inhibitor, CP-690,550, in rat adjuvant-induced arthritis","volume":"7","author":"Meyer","year":"2010","journal-title":"J Inflamm [Lond]"},{"key":"key\n\t\t\t\t2018121209541492500_CIT0005","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1016\/j.cgh.2014.01.029","article-title":"A phase 2 study of tofacitinib, an oral janus kinase inhibitor, in patients with Crohn\u2019s disease","volume":"12","author":"Sandborn","year":"2014","journal-title":"Clin Gastroenterol Hepatol"},{"key":"key\n\t\t\t\t2018121209541492500_CIT0006","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1056\/NEJMoa1606910","article-title":"Tofacitinib as induction and maintenance therapy for ulcerative colitis","volume":"376","author":"Sandborn","year":"2017","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2018121209541492500_CIT0007","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/S0140-6736(16)32537-5","article-title":"Clinical remission in patients with moderate-to-severe Crohn\u2019s disease treated with filgotinib [the FITZROY study]: results from a phase 2, double-blind, randomised, placebo-controlled trial","volume":"389","author":"Vermeire","year":"2017","journal-title":"Lancet"},{"key":"key\n\t\t\t\t2018121209541492500_CIT0008","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1053\/j.gastro.2005.06.021","article-title":"The clustering of other chronic inflammatory diseases in inflammatory bowel disease: a population-based study","volume":"129","author":"Bernstein","year":"2005","journal-title":"Gastroenterology"},{"key":"key\n\t\t\t\t2018121209541492500_CIT0009","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1111\/j.1572-0241.2001.03756.x","article-title":"The prevalence of extraintestinal diseases in inflammatory bowel disease: a population-based study","volume":"96","author":"Bernstein","year":"2001","journal-title":"Am J Gastroenterol"},{"key":"key\n\t\t\t\t2018121209541492500_CIT0010","first-page":"297","article-title":"Extraintestinal manifestations in inflammatory bowel disease: differences between Crohn\u2019s disease and ulcerative colitis","volume":"125","author":"Mendoza","year":"2005","journal-title":"Med Clin [Barc]"},{"key":"key\n\t\t\t\t2018121209541492500_CIT0011","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1097\/00054725-200405000-00005","article-title":"Autoimmune disorders and extraintestinal manifestations in first-degree familial and sporadic inflammatory bowel disease: a case-control study","volume":"10","author":"Ricart","year":"2004","journal-title":"Inflamm Bowel Dis"},{"key":"key\n\t\t\t\t2018121209541492500_CIT0012","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1016\/0016-5085(79)90391-3","article-title":"National Cooperative Crohn\u2019s Disease Study: extraintestinal manifestations and perianal complications","volume":"77","author":"Rankin","year":"1979","journal-title":"Gastroenterology"},{"key":"key\n\t\t\t\t2018121209541492500_CIT0013","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/S0889-8553(01)00019-X","article-title":"Extraintestinal manifestations of inflammatory bowel disease","volume":"31","author":"Su","year":"2002","journal-title":"Gastroenterol Clin North Am"},{"key":"key\n\t\t\t\t2018121209541492500_CIT0014","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1097\/00004836-199607000-00009","article-title":"Immune-related systemic manifestations of inflammatory bowel disease. A prospective study of 792 patients","volume":"23","author":"Veloso","year":"1996","journal-title":"J Clin Gastroenterol"},{"key":"key\n\t\t\t\t2018121209541492500_CIT0015","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1038\/ajg.2010.343","article-title":"Frequency and risk factors for extraintestinal manifestations in the Swiss inflammatory bowel disease cohort","volume":"106","author":"Vavricka","year":"2011","journal-title":"Am J Gastroenterol"},{"key":"key\n\t\t\t\t2018121209541492500_CIT0016","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1111\/j.1365-2249.2010.04201.x","article-title":"Role of inflammatory cells, cytokines and matrix metalloproteinases in neutrophil-mediated skin diseases","volume":"162","author":"Marzano","year":"2010","journal-title":"Clin Exp Immunol"},{"key":"key\n\t\t\t\t2018121209541492500_CIT0017","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1111\/cei.12394","article-title":"Expression of cytokines, chemokines and other effector molecules in two prototypic autoinflammatory skin diseases, pyoderma gangrenosum and Sweet\u2019s syndrome","volume":"178","author":"Marzano","year":"2014","journal-title":"Clin Exp Immunol"},{"key":"key\n\t\t\t\t2018121209541492500_CIT0018","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.cgh.2016.06.025","article-title":"Systematic review of tumor necrosis factor antagonists in extraintestinal manifestations in inflammatory bowel disease","volume":"15","author":"Peyrin-Biroulet","year":"2017","journal-title":"Clin Gastroenterol Hepatol"},{"key":"key\n\t\t\t\t2018121209541492500_CIT0019","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/ibd.21663","article-title":"Adalimumab produces clinical remission and reduces extraintestinal manifestations in Crohn\u2019s disease: results from CARE","volume":"18","author":"L\u00f6fberg","year":"2012","journal-title":"Inflamm Bowel Dis"},{"key":"key\n\t\t\t\t2018121209541492500_CIT0020","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1056\/NEJMoa1109071","article-title":"Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis","volume":"367","author":"Fleischmann","year":"2012","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2018121209541492500_CIT0021","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/S0140-6736(14)62113-9","article-title":"Tofacitinib vs etanercept or placebo in moderate-to-severe chronic plaque psoriasis: a phase 3 randomised non-inferiority trial","volume":"386","author":"Bachelez","year":"2015","journal-title":"Lancet"},{"key":"key\n\t\t\t\t2018121209541492500_CIT0022","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1093\/ecco-jcc\/jjw168","article-title":"Third European evidence-based consensus on the diagnosis and management of Crohn\u2019s disease 2016. Part 1: Diagnosis and medical management","volume":"11","author":"Gomoll\u00f3n","year":"2017","journal-title":"J Crohns Colitis"},{"key":"key\n\t\t\t\t2018121209541492500_CIT0023","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1093\/ecco-jcc\/jjx008","article-title":"Third European evidence-based consensus on diagnosis and management of ulcerative colitis. Part 1: Definitions, diagnosis, extra-intestinal manifestations, pregnancy, cancer surveillance, surgery, and ileo-anal pouch disorders","volume":"11","author":"Magro","year":"2017","journal-title":"J Crohns Colitis"},{"key":"key\n\t\t\t\t2018121209541492500_CIT0024","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1056\/NEJM198712243172603","article-title":"Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study","volume":"317","author":"Schroeder","year":"1987","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2018121209541492500_CIT0025","doi-asserted-by":"crossref","first-page":"2462","DOI":"10.1056\/NEJMoa050516","article-title":"Infliximab for induction and maintenance therapy for ulcerative colitis","volume":"353","author":"Rutgeerts","year":"2005","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2018121209541492500_CIT0026","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1136\/gut.30.7.983","article-title":"Development and validation of an endoscopic index of the severity for Crohn\u2019s disease: a prospective multicentre study. Groupe d\u2019Etudes Th\u00e9rapeutiques des Affections Inflammatoires du Tube Digestif [GETAID]","volume":"30","author":"Mary","year":"1989","journal-title":"Gut"},{"key":"key\n\t\t\t\t2018121209541492500_CIT0027","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1002\/ibd.20312","article-title":"Crohn\u2019s disease activity assessed by fecal calprotectin and lactoferrin: correlation with Crohn\u2019s disease activity index and endoscopic findings","volume":"14","author":"Sipponen","year":"2008","journal-title":"Inflamm Bowel Dis"},{"key":"key\n\t\t\t\t2018121209541492500_CIT0028","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1038\/nrd1254","article-title":"Tissue microarrays in drug discovery","volume":"2","author":"Sauter","year":"2003","journal-title":"Nat Rev Drug Discov"},{"key":"key\n\t\t\t\t2018121209541492500_CIT0029","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1186\/1471-2407-10-93","article-title":"Role of the VEGF ligand to receptor ratio in the progression of mismatch repair-proficient colorectal cancer","volume":"10","author":"Eppenberger","year":"2010","journal-title":"BMC Cancer"},{"key":"key\n\t\t\t\t2018121209541492500_CIT0030","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1002\/ijc.24842","article-title":"Is the improved prognosis of p16 positive oropharyngeal squamous cell carcinoma dependent of the treatment modality","volume":"126","author":"Fischer","year":"2010","journal-title":"Int J Cancer"},{"key":"key\n\t\t\t\t2018121209541492500_CIT0031","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.2174\/1389450115666140908125453","article-title":"Biologics for extraintestinal manifestations of IBD","volume":"15","author":"Vavricka","year":"2014","journal-title":"Curr Drug Targets"},{"key":"key\n\t\t\t\t2018121209541492500_CIT0032","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1136\/gut.2005.074815","article-title":"Infliximab for the treatment of pyoderma gangrenosum: a randomised, double blind, placebo controlled trial","volume":"55","author":"Brooklyn","year":"2006","journal-title":"Gut"},{"key":"key\n\t\t\t\t2018121209541492500_CIT0033","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1097\/MIB.0000000000001109","article-title":"Anti-TNF treatment for extraintestinal manifestations of inflammatory bowel disease in the Swiss IBD Cohort Study","volume":"23","author":"Vavricka","year":"2017","journal-title":"Inflamm Bowel Dis"},{"key":"key\n\t\t\t\t2018121209541492500_CIT0034","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1136\/gut.34.12.1705","article-title":"Location of tumour necrosis factor alpha by immunohistochemistry in chronic inflammatory bowel disease","volume":"34","author":"Murch","year":"1993","journal-title":"Gut"},{"key":"key\n\t\t\t\t2018121209541492500_CIT0035","doi-asserted-by":"crossref","first-page":"S396","DOI":"10.1016\/S0016-5085(17)31562-7","article-title":"DOP025 Efficacy of vedolizumab on extraintestinal manifestation in patients with inflammatory bowel disease: a post-hoc analysis of the OBSERV-IBD cohort from the GETAID","volume":"152","author":"Tadbiri","year":"2017","journal-title":"Gastroenterology"},{"key":"key\n\t\t\t\t2018121209541492500_CIT0036","doi-asserted-by":"crossref","first-page":"2166","DOI":"10.1038\/jid.2012.130","article-title":"Incidence, mortality, and disease associations of pyoderma gangrenosum in the United Kingdom: a retrospective cohort study","volume":"132","author":"Langan","year":"2012","journal-title":"J Invest Dermatol"},{"key":"key\n\t\t\t\t2018121209541492500_CIT0037","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1016\/j.cgh.2015.06.001","article-title":"Defining disease severity in inflammatory bowel diseases: current and future directions","volume":"14","author":"Peyrin-Biroulet","year":"2016","journal-title":"Clin Gastroenterol Hepatol"}],"container-title":["Journal of Crohn's and Colitis"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ecco-jcc\/article-pdf\/12\/3\/347\/27097407\/jjx158.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,27]],"date-time":"2025-06-27T00:38:07Z","timestamp":1750984687000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/article\/12\/3\/347\/4647660"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12,21]]},"references-count":37,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2017,12,21]]},"published-print":{"date-parts":[[2018,2,28]]}},"URL":"https:\/\/doi.org\/10.1093\/ecco-jcc\/jjx158","relation":{},"ISSN":["1873-9946","1876-4479"],"issn-type":[{"value":"1873-9946","type":"print"},{"value":"1876-4479","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2018,3]]},"published":{"date-parts":[[2017,12,21]]}}}